Benefits
Traditional Immune Support
Pau D'Arco has been used in traditional South American medicine as a general immune tonic. Preclinical evidence shows naphthoquinones can inhibit growth of certain bacteria, yeasts, and parasites in vitro, which informs the supplement's marketed immune-support positioning.
Antifungal Tradition
Lapachol and related quinones display activity against Candida and other fungi in laboratory assays. Pau D'Arco is widely used in folk and integrative practice for yeast-balance protocols, though high-quality human trial data is limited.
Antioxidant Bark Compounds
The polyphenolic and quinone fraction of Pau D'Arco bark exhibits free-radical scavenging activity in vitro. This may contribute to its traditional reputation as a 'cleansing' or restorative tonic in indigenous and folk practice.
Inflammation-Modulating Activity
Naphthoquinones from the bark have shown anti-inflammatory effects in preclinical models, including suppression of NF-kB signaling and reduction of inflammatory cytokine production. Clinical translation to human supplement use remains preliminary.
Mechanism of action
Naphthoquinone Redox Cycling
Lapachol and beta-lapachone undergo enzymatic redox cycling, generating reactive oxygen species that can selectively damage microbial and tumor cells. This mechanism underlies the bark's traditional antimicrobial use but also contributes to systemic toxicity at higher doses.
Topoisomerase Inhibition
Beta-lapachone inhibits topoisomerase I, a DNA-processing enzyme upregulated in rapidly dividing cells. This action was the basis for early preclinical anticancer interest, though clinical development was limited by off-target toxicity.
Anti-Vitamin-K Activity
Lapachol's quinone structure resembles vitamin K and competes with K-dependent clotting factor activation, prolonging prothrombin time at higher doses. This pharmacologic effect was a documented dose-limiting toxicity in the historical NCI Phase I trial.
NQO1 Substrate
Beta-lapachone is a substrate for NAD(P)H quinone dehydrogenase 1 (NQO1), an enzyme often elevated in stressed or transformed cells. NQO1-mediated bioactivation generates oxidative stress preferentially in tissues expressing this enzyme.
Clinical trials
Phase I clinical trial conducted in the 1970s by the National Cancer Institute investigating lapachol (the major naphthoquinone from Pau D'Arco) for anticancer activity in patients with advanced malignancies.
Adults with advanced solid tumors in early-phase oncology testing.
Lapachol produced dose-limiting toxicity, including prothrombin-time prolongation consistent with anti-vitamin-K effects, anemia, and gastrointestinal symptoms. Development was discontinued. The trial establishes that the active naphthoquinone from Pau D'Arco produces measurable systemic effects at supratherapeutic doses and informs current safety framing — particularly the contraindication with anticoagulant therapy.
Series of in vitro and animal studies evaluating Pau D'Arco bark extract and isolated naphthoquinones against bacterial, fungal, and parasitic organisms.
Cell culture and rodent infection models.
Pau D'Arco extracts and isolated lapachol/beta-lapachone show measurable inhibitory activity against Candida albicans, Staphylococcus aureus, and select parasites in laboratory assays. Animal models suggest some in vivo efficacy. Translation to clinical antimicrobial dosing in humans has not been established by controlled trials.